Idexx Laboratories — Q3 2024 Earnings Presentation

4 slides from Idexx Laboratories's earnings presentation, Oct 31, 2024

Slide 1: IDEXX Q3 2024 Earnings Highlights
IDEXX Q3 2024 Earnings Highlights (NASDAQ: (NASDAQ: IDXX) IDXX) Operating Diluted Revenue Profit Earnings Per Share $976M $304M $2.80 Reported growth: +7% 31.2% of Revenue Reported growth: +11% Organic growth: +6% YoY change in basis points: CAG Diagnostics Recurring Reported +110 bps Comparable gro
Slide 2: 2024 Growth and Financial Performance Outlook
IDEXX Q3 2024 Earnings Highlights (NASDAQ: IDXX) 2024 Growth and Financial Performance Outlook Commentary • Updates full year P&L guidance to incorporate more recent sector growth trends and sustained outlook for strong comparable operating margin and EPS gains ◦ Updates revenue guidance to $3,865 m
Slide 3: U.S. Companion Animal Practice Growth Update
t++eeteteet U.S. Companion Animal Practice Growth Update As of September 30, 2024 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* 20% 15% 12.3% Practice Revenue 10% 4.6% >-2% 5% 3.3% 3.3% 5 G97 0% Total Visits 0.8% 5% 53% 2.25 2.4% -2.1% -2.34 Qi a2 03
Slide 4: Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice
t+t+tteeeet U.S. Companion Animal Practice Growth Update As of September 30, 2024 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** Q3’2024 Year-Over-Year Growth (%) + 6.0% + 3.5% —lcUr 0.5% - 2.0% + 8.0% +7.0% Q3’2023 as -15% + 6.0% + 11.0% Q3 Average 2019-2022 + 2.0% C